- ASSISTANT PROFESSOR Microbiology
NIAID, National Institutes of Health
Ph.D., University of Maryland
- West Nile virus (WNV) is a highly virulent re-emerging human pathogen and the leading cause of arthropod-borne encephalitis in the US. Neither vaccines nor antiviral or immunomodulator therapies are available for WNV, and new concepts based on precise understanding of molecular pathogenesis are needed. WNV causes meningitis and multifocal encephalitis in both human disease and mouse models, characterized by the accumulation of leukocytes, including monocytes and T cells, in the brain. The major research goals of my laboratory are to 1) understand leukocyte trafficking events, both at the molecular and cellular level, as they relate to host defense against WNV; 2) understand host genetic susceptibility to WNV; and 3) develop new models to evaluate WNV and otherh flavivirus infection. The primary tools used to evaluate these questions are a well-established mouse model of WNV infection, samples acquired from WNV-infected individuals, and an ex vivo model of WNV infection in human lymphoid tissue. A combination of these approaches will provide a comprehensive understanding of WNV pathogenesis and virus-host interactions.
Watch a video featuring the Microbiology and Virology PhD
Graduate School Program.
Bardina SV, Lim JK. The role of chemokines in the pathogenesis of neurotropic flaviviruses. Immunol Res 2012 May;.
Lionakis MS, Fischer BG, Lim JK, Swamydas M, Wan W, Richard Lee CC, Cohen JI, Scheinberg P , Gao JL, Murphy PM. Chemokine Receptor Ccr1 Drives Neutrophil-mediated Kidney Immunopathology and Mortality in Invasive Candidiasis. PLoS Path 2012 Aug; 8(8).
Wan W, Lim JK, Lionakis MS, Rivollier A, McDermott DH, Kelsall BL, Farber JM, Murphy PM. Genetic Deletion of Chemokine Receptor Ccr6 Decreases Atherogenesis in ApoE-Deficient Mice. Circ Res 2011 Jun;.
Lim JK, Murphy PM. Chemokine control of West Nile virus infection. Exp Cell Res 2011 Mar; 317(5): 569-74.
Lim JK, Obara CJ, Rivolier A, Pletnev AG, Murphy PM. Chemokine receptor Ccr2 is critical for monocyte accumulation and survival in West Nile virus encephalitis. J Immunol 2011 Jan; 186(1): 471-478.
Lionakis MS, Lim JK, Lee CC, Murphy PM. Organ-Specific Innate Immune Responses in a Mouse Model of Invasive Candidiasis.. J Innate Immun 2010 Nov; 3(2): 180-99.
Butts CL, Jones YL, Lim JK, Salter CE, Belyavskaya E, Sternberg EM. Tissue expression of steroid hormone receptors is associated with differential immune responsiveness. Brain Behav Immun 2010 Nov;.
Lim JK, McDermott DH, Lisco A, Foster GA, Krysztof D, Follmann D, Stramer SL, Murphy PM. CCR5 deficiency is a risk factor for early clinical manifestations of West Nile virus infection but not for viral transmission. J Infect Dis 2010 Jan; 201(2): 178-185.
Lim JK, Lisco A, McDermott DH, Huynh L, Ward JM, Johnson B, Johnson H, Pape J, Foster GA, Kryztof D, Follmann D, Stramer SL, Margolis LB, Murphy PM. Genetic variation in OAS1 is a risk factor for initial infection with West Nile virus in man. PLoS Pathog 2009 Feb; 5(2:e1000321).
Lim JK, Louie CY, Glaser C, Jean C, Johnson B, Johnson H, McDermott DH, Murphy PM. Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic. J Infect Dis 2008 Jan; 197(2): 262-265.
Lambert JS, Machado ES, Watson DC, Sill AM, Lim JK, Charurat M, Cunha SM, Afonso AO, Oliviera RH, Tanuri A, DeVico AL. Production of the HIV-suppressive chemokines CCL3/MIP-1alpha and CCL22/MDC is associated with more effective antiretroviral therapy in HIV-infected children. Pediatr Infect Dis J 2007 Oct; 26(10): 936-44.
Lim JK, Lu W, Hartley O, DeVico AL. N-terminal proteolytic processing by cathepsin G converts RANTES/CCL5 and related analogs into a truncated 4-68 variant. J Leukoc Biol 2006 Dec; 80(6): 1395-404.
Tikhonov I, Deetz CO, Paca R, Berg S, Lukyanenko V, Lim JK, Pauza CD. Human Vgamma2Vdelta2 T cells contain cytoplasmic RANTES.. Int Immunol 2006 Aug; 18(8): 1243-51.
Lim JK, Glass WG, McDermott DH, Murphy PM. CCR5: no longer a good-for-nothing gene--chemokine control of West Nile virus infection. Trends Immunol 2006 Jul; 27(7): 308-312.
Glass WG, McDermott DH, Lim JK, Lekhong S, Yu SF, Frank WA, Pape J, Cheshier RC, Murphy PM. CCR5 deficiency increases risk of symptomatic West Nile virus infection.. J Exp Med 2006 Jan; 203(1): 35-40.
Glass* WG, Lim* JK, Cholera R, Pletnev AG, Gao JL, Murphy PM. Chemokine receptor CCR5 promotes leukocyte trafficking to the brain and survival in West Nile virus infection.. J Exp Med 2005 Oct; 202(8): 1087-1098.
Lim JK, Burns JM, Lu W, DeVico AL. Multiple pathways of amino terminal processing produce two truncated variants of RANTES/CCL5. J Leukoc Biol 2005 Aug; 78(2): 442-52.
Berlyn KA, Ponniah S, Stass SA, Malone JG, Hamlin-Green G, Lim JK, Cottler-Fox M, Tricot G, Alexander RB, Mann DL, Malone RW. Developing dendritic cell polynucleotide vaccination for prostate cancer immunotherapy.. J Biotechnol 1999 Aug; 73(2-3): 155-79.
Lim JK, Hunter J, Fernandez-Vina M, Mann DL. Characterization of LMP polymorphism in homozygous typing cells and a random population.. Hum Immunol 1999 Feb; 60(2): 145-51.
Lim JK, Gunther NW 4th, Zhao H, Johnson DE, Keay SK, Mobley HL. In vivo phase variation of Escherichia coli type 1 fimbrial genes in women with urinary tract infection.. Infect Immun 1998 Jul; 66(7): 3303-10.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Dr. Lim did not report having any of the following types of financial relationships with industry during 2014 and/or 2015: consulting, scientific advisory board, industry-sponsored lectures, service on Board of Directors, participation on industry-sponsored committees, equity ownership valued at greater than 5% of a publicly traded company or any value in a privately held company. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Mount Sinai Health System (MSHS) physicians - including those employed by MSHS - do not always participate in the same health plans in which MSHS hospitals or facilities participate.
Information regarding insurance participation and billing by this physician may be found on this page or obtained by contacting this provider directly.
Insurance plans that the Mount Sinai Health System hospitals or facilities participate in can be found on the Mount Sinai Health System website.
Annenberg Building Floor 16 Room 40
1468 Madison Avenue
New York, NY 10029